A scientific review of 897 cancer patients treated with various formulations of Coley Fluid up to 110 years ago found that complete regression and 5-year survival occurred in 46% of the 523 inoperable cases and 51% of the 374 operable cases. These results are comparable to modern 5-year survival rates. The National Cancer Institute estimates overall 5-year cancer survival at 35% in 1950-54 and 63.8% in 1992-98.

 To determine comparable rates of 10-year survival, in 1999 researchers compared Coley Fluid patients with matched controls from the National Cancer Institute’s Surveillance Epidemiology End Result database. The study found higher rates of 10-year survival for Coley Fluid patients compared to modern patients in kidney cancer (33% to 23%), ovarian cancer (55% to 29%) and sarcoma (50% to 38%).

 However, retrospective studies underestimate the efficacy of Coley Fluid because:

•  There was a wide variability in potency between the more than 20 different formulations of Coley Fluid used to treat cancer patients.

• There was no standard clinical protocol for the administration of Coley Fluid.

 If Coley Fluid patients fared as well as modern cancer patients in spite of variations in formulation and clinical protocol, patients receiving an optimized version of Coley Fluid under a proper clinical protocol should fare even better.

To illustrate the importance of formulation, the chart below compares 5-year survival rate by formulation for 137 historical sarcoma patients who received Coley Fluid therapy:

To illustrate the importance of clinical protocol, the chart below compares 5-year survival rate by length of therapy for the same group of historical sarcoma patients:

There have been 63 cases of advanced breast cancer treated with Coley Fluid. Of these cases, the subsequent histories of the 37 patients who received effective formulations were significantly better compared to the 26 patients who received ineffective formulations.

In these charts, the column “apparent cure” refers to patients who had no evidence of disease at the time of their last known medical examination (average 7.8 years after therapy), and the column “more than 2” refers to patients who survived more than 2 years (average survival of these six patients was 8.1 years).

When the eventual fate of these 63 patients is considered in terms clinical protocol, patients treated for at least three months fared much better than those treated for less than three months.

Finally, when we analyze the subsequent histories of advanced breast cancer patients treated with both an effective version of Coley Fluid and for 3 months or longer, the results are very promising.